PTPN11 and neoplasm: SHP2 inhibitors, as discussed above, are another example of vertical pathway inhibition of RTK activation of RAS proteins (54), but SHP2 inhibitors do not block the adaptive transcriptional activation that leads to a functional phenotypic state change of the tumor cell.